WallStSmart

DexCom Inc (DXCM)vsINVO Fertility, Inc. (IVF)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 65882% more annual revenue ($4.97B vs $7.53M). DXCM leads profitability with a 20.1% profit margin vs -70.2%. DXCM earns a higher WallStSmart Score of 74/100 (B).

DXCM

Strong Buy

74

out of 100

Grade: B

Growth: 8.0Profit: 8.5Value: 5.0Quality: 6.5
Piotroski: 5/9Altman Z: 2.67

IVF

Hold

38

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -6.79

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DXCM4 strengths · Avg: 8.8/10
Return on EquityProfitability
38.1%10/10

Every $100 of equity generates 38 in profit

Profit MarginProfitability
20.1%9/10

Keeps 20 of every $100 in revenue as profit

Operating MarginProfitability
24.3%8/10

Strong operational efficiency at 24.3%

EPS GrowthGrowth
43.6%8/10

Earnings expanding 43.6% YoY

IVF3 strengths · Avg: 9.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

Areas to Watch

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
33.4x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.9x4/10

Trading at 11.9x book value

IVF4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.53M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-1.29M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.

Bull Case : IVF

The strongest argument for IVF centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 16.7% demonstrates continued momentum.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Bear Case : IVF

The primary concerns for IVF are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

DXCM profiles as a mature stock while IVF is a growth play — different risk/reward profiles.

IVF is growing revenue faster at 16.7% — sustainability is the question.

DXCM generates stronger free cash flow (185M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

DXCM scores higher overall (74/100 vs 38/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

INVO Fertility, Inc.

HEALTHCARE · MEDICAL DEVICES · USA

INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. The company is headquartered in Sarasota, Florida.

Want to dig deeper into these stocks?